The Renin-Angiotensin System (RAS) medicine market in Norway showed steady sales for the years leading up to 2023. Sales in 2023 stood at 570.0 million Norwegian Krones (MNOK). Moving into the forecast period from 2024 to 2028, the market is anticipated to maintain moderate growth. The year-on-year variation for 2024 and 2025 is 0%, reflecting stabilization. From 2026 to 2027, sales show negligible growth of approximately 0.17%, and from 2027 to 2028, the growth remains flat at 0%. The compound annual growth rate (CAGR) over the next five years is about 0.14% annually.

Future trends to watch for:

Technological advancements in RAS medicine delivery and formulation.
Policy changes or healthcare reforms impacting pharmaceutical pricing and reimbursement schemes in Norway.
Emerging competition from biosimilars or newer therapeutic classes targeting similar health conditions.
Potential demographic shifts such as an aging population, which may drive demand for cardiovascular medications like those impacting the RAS.